Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
2.050
+0.030 (1.49%)
At close: Mar 9, 2026, 4:00 PM EDT
2.060
+0.010 (0.49%)
After-hours: Mar 9, 2026, 4:55 PM EDT
Pulmatrix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
7.49M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| Addex Therapeutics | 198.82K |
| Kiora Pharmaceuticals | 20.00K |
| Alaunos Therapeutics | 6.00K |
| Ernexa Therapeutics | 1,000.00 |
PULM News
- 7 days ago - Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities - PRNewsWire
- 11 days ago - Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives - PRNewsWire
- 5 months ago - Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PRNewsWire
- 7 months ago - Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - PRNewsWire
- 10 months ago - Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - PRNewsWire
- 10 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
- 1 year ago - Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PRNewsWire